Institute of Diagnostic Radiology, Erlangen University Hospital, Erlangen, Germany.
Eur Radiol. 2011 Jun;21(6):1180-7. doi: 10.1007/s00330-010-2016-z. Epub 2010 Dec 30.
Tumour size estimates using mammography (MG), conventional ultrasound (US), compound imaging (CI) and real-time elastography (RTE) were compared with histopathological specimen sizes.
The largest diameters of 97 malignant breast lesions were measured. Two US and CI measurements were made: US1/CI1 (hypoechoic nucleus only) and US2/CI2 (hypoechoic nucleus plus hyperechoic halo). Measurements were compared with histopathological tumour sizes using linear regression and Bland-Altman plots.
Size prediction was best with ultrasound (US/CI/RTE: R (2) 0.31-0.36); mammography was poorer (R(2) = 0.19). The most accurate method was US2, while US1 and CI1 were poorest. Bland-Altman plots showed better size estimation with US2, CI2 and RTE, with low variation, while mammography showed greatest variability. Smaller tumours were better assessed than larger ones. CI2 and US2 performed best for ductal tumours and RTE for lobular cancers. Tumour size prediction accuracy did not correlate significantly with breast density, but on MG tumours were more difficult to detect in high-density tissue.
The size of ductal tumours is best predicted with US2 and CI2, while for lobular cancers RTE is best. Hyperechoic tumour surroundings should be included in US and CI measurements and RTE used as an additional technique in the clinical staging process.
比较乳腺钼靶(MG)、常规超声(US)、复合成像(CI)和实时弹性成像(RTE)对肿瘤大小的估计与组织病理学标本大小的差异。
测量 97 个恶性乳腺病变的最大直径。进行了两次 US 和 CI 测量:US1/CI1(仅低回声核)和 US2/CI2(低回声核加高回声晕)。采用线性回归和 Bland-Altman 图比较超声(US/CI/RTE:R²=0.31-0.36)、乳腺钼靶(R²=0.19)与组织病理学肿瘤大小的关系。
超声(US/CI/RTE:R²=0.31-0.36)预测肿瘤大小的效果最好,乳腺钼靶(R²=0.19)预测效果较差。最准确的方法是 US2,而 US1 和 CI1 预测效果最差。Bland-Altman 图显示,US2、CI2 和 RTE 具有较低的变异性,能够更好地进行尺寸估计,而乳腺钼靶则具有更大的变异性。小肿瘤比大肿瘤评估更准确。CI2 和 US2 对导管癌的预测效果最好,RTE 对小叶癌的预测效果最好。肿瘤大小预测的准确性与乳腺密度无显著相关性,但在乳腺钼靶中,高密度组织中的肿瘤更难检测。
US2 和 CI2 对导管癌的大小预测效果最佳,而 RTE 对小叶癌的预测效果最佳。US 和 CI 测量应包括高回声肿瘤周围组织,RTE 可作为临床分期过程中的附加技术。